Executive Summary Ivory Graft

IVORYGraft

Achievements

- Ivory Dentin Graft™ is approved under EU MDR 2017/745. CE approval is expected during June 2022
- Successful randomized, semi-double blinded clinical study with superior results

Business and Product Description

› Ivory Graft is a company established in 2013 at Israel, which developed a novel bioresorbable bone graft material for the repair or augmentation of bone defects in dental procedures: Ivory Dentin Graft™ .

› Ivory Dentin Graft™ breakthrough product consists of sterile granules of hydroxyapatite, which retain the natural form of the sourced porcine dentin as well as the natural protein matrix which largely consists of porcine collagen

Current Products

› Packed Ivory Dentin Graft™ Vials (0.25, 0.5, 1.0, 2.0, 5.0 gr)

› Packed Ivory Dentin Graft™ Syringe (0.5, 1.0 gr)

Opportunity

Off-the-shelf ready to use product with beneficial organic properties, most common and favorable in the market mainly in Asia Pacific. Current global market valued at 500M $ expected to reach 750M $ in 2026 (CAGR > 7.8%)

Future Pipeline

Bone Graft material for Orthopedic indications (fast growing ageing population with a global current market of ~3 Billion $)

Our Solution

Use of Ivory Dentin Graft – tooth derived graft material in the dental procedures.

Our Vision

We aim to become an innovative and global leader in the field of Dentin Bone Graft. Our mission is to make a difference in a patient's life and improve the quality of their life. We are committed to avoid complacency, choosing instead to stay on the cutting edge and best treatment modalities, materials and technology.

Why Ivory Dentin Graft™

- Provides a unique strength and flexibility structure due to its high chemical and mechanical similarity to human jaw bone dentin.
- Dentin is a relatively compact material that offers good structural stability and is more slowly resorbed than bone.

Our Core Team



Meir Sahar
Biz. Dev.

Prof. Gerard Scortecci
Scientific advisor & share-holder

Yaron Itzhari
President

Dr. G.M. Stern
Scientific advisor & share-holder



Eyal Miller
CEO

Liya Greenberg
QA/RA Director

Dr. Lari Sapoznikov-
CCO

Lets Partner With Us

Address: 1 Hatachana Kfar Saba , Israel

Call: +972-52-5628562

Email: eyal@ivorygraft.com

IVORYGraft

Global Dental Bone Graft Substitutes Market Revenue, 2021 - 2026 (USD Million)



Source: Zion Market Research, 2021

Bone graft: Current Solutions

- *Autograft: bone or dentin*

Disadvantage: very limited amount, painful for bone grafting

- *Allograft: bone (mainly of corpses)*

Disadvantage: expensive, limited amount, risk of human-to-human disease

- *Xenograft: bone origin (mainly bovine and porcine)*

Opportunity: Off-the-shelf ready to use product, most common and favorable in the market mainly in Asia Pacific.

- *Synthetic: variety of materials, generally hydroxyapatite*

Disadvantage: non-organic material

Ivory Graft Clinical Study (Assaf Harofeh Medical Center): Safety and Efficacy Evaluation of the Ivory Dentin Graft™ Device



The biopsy samples obtained from Ivory graft ™ group has significant osteogenic activity with better integration scores compared to the comparator group



The amount of new bone formation in alveolar bone core biopsies obtained from subjects from the Ivory graft ™ group was higher than the comparator group

[From the literature: Santos A, et al. Clin Oral Implants Res. 2021 May.]:

A Randomized controlled clinical trial with an 18 months follow-up showed that ***mineralized dentin matrix*** *(MDM) had a significantly higher quantity of newly formed bone and lower amount of residual graft in histomorphometry results and equal clinical and patient related outcomes.*

CLINICAL ORAL IMPLANTS RESEARCH WILEY

Advantages of Dentin vs. Bone derived material:

1. *Harder natural material that provides structural support with slower resorption to support host bone growth*
2. *Dentin microstructure has pores that allow good vessel ingrowth*
3. *Excellent integration of regenerated bone with the implants*
4. *Similar side effect profile to other materials*